Journal of Acquired Immune Deficiency Syndromes ; JAIDS 2001: Vol 26 Index

13 Pages·2001·3.9 MB·English

JAIDS Journal of Acquired Immune Deficiency Syndromes
26:517-520© 2001 Lippincott Williams & Wilkins, Inc., Philadelphia
Journal of Acquired Immune Deficiency Syndromes
Volume 26, 2001
Author Index
Aarnoutse RE, 218 Bollinger R, 21 Clinical Epidemiology Group from the
Abgrall S, 151 Bollinger RC, 352 French Hospital Database on HIV,
Abrams DI, 443 Bonacini M, 340 151
Adjé C, 501 Bonhoeffer S, 397 Cohen M, 28
Agbalika F, 182 Booth RE, 483 Collier AC, 320
Alcantara LCJ, 490 Boros S, 473 Col6n HM, 164
Algren H, 443 Boutwell RC, 263 Costagliola D, 130, 151
Altmann D, 266 Brand D, 413 Coulaud JP, 130
Ammassari A, 326 Briones C, 145 Coulibaly M, 501
An P, 507 Brookmeyer RS, 352 Coull JJ, 423
Anastos K, 28 Brown AE, 345
Andia J, 164 Brown G, 236
D’ Angelo LJ, 449
Antinori A, 326 Brown T, 93
Appelberg R, 300 Brunet S, 413 Daar ES, 466
APROCO Study Group, The 480 Brunn M, 266 Damas CD, 185
Arkin S, 466 Buapunth P, 345 Darioli R, 389
Darragh T, 256
Augenbraun M, 28 Buchanan RJ, 246
Aung H, 305 Bucher HC, 191 de Goér M-G, 303
Azzari C, 196 Burger DM, 218 De Luca A, 326
Buzelay L, 413 de Martino M, 196
Bwayo JJ, 360 de Souza MS, 345
Ba DS, 130 De Vroey V, 495
Baeten JM, 360 Deeks SG, S25
Bahula C, 8 Cadorin L, 299 Dehertogh P, 495
Bala M, 393 Cagle HH, 515 DeHovitz JA, 390
Bangsberg DR, 435 Caldwell P, 332 del Romero J, 145
Bankson DD, 360 Cao Ys] Delaporte E, 36
Barak Y, 111 Chadapaud S, 44 Delbeke E, 44
Barbouche RM, 298 Chang CJ, 291 Delfraissy JF, 303
Barin F, 413 Charlebois ED, 435 Dellagi K, 298
Barlow KL, 381 Cheingsong R, 501 Demant T, 225
Barreiro P, 391 Chen J, 365 Demeter L, $3, S51
Basséne E, 130 Chen S-C, 274 Demouchy C, 193
Battegay M, 191 Chen Yi-Ming A, 274 Deren S, 164
Becker SL, 72 Chéne G, 480 Detels R, 82
Bedynek A, 225 Chernoff D, 466 Devereux H, 159
Belda FJ, 381 Chesney M, 435 di Gennaro G, 299
Bennett CL, 390 Chirenje Z, 21 Di Lonardo AM, 193
Bentwich Z, 11] Chorba T, 501 Diagbouga S, 193
Berhane K, 28 CHORUS Program Team, 7 Didier J-M, 193
Betts MR, 423 Chouraqui M, 44 Dieleman JP, 218
Biggar RJ, 371 Chuang Y-C, 274 Dieterich DT, 208
Bissagene E, 501 Churchill D, 462 Divekar AD, 352
Bittencourt AL, 490 Ciccarone D, 435 Djomand G, 501
Blasi E, 300 Cingolani A, 326 Donfield S, 449, 466
Blok WL, 218 Clague H, 435 Dore GJ, 283
Bloor S, 495 Clark RA, 513 Dorrucci M. 377
Boelaert JR, 300 Clewley JP, 381 Doser N, 389
Bogner J, 225 Cliffe S, 381 Dourado I, 490
518 AUTHOR INDEX
Downing R, 495 Hammill H, 236 Ketoff NR, 305
Drew WL, 320 Hamouda O, 266 Khalilli K, 507
Drobacheff C, 137 Handzel ZT, 111 Khanani F, 63
Dupont C, 151 Hiinsel A, 191 Kim S-H, 256
Duwe S, 266 Hansen NI, 72 Kingsley L, 82
Harbke CR, 515 Kityo CM, 495
Easterbrook P, 462 Hashimoto H, 512 Kleeberger CA, 82
Eholie S, 501 Haubrich R, 458 Klein D, 8
Emrick CB, 63 Haubrich R, $3, S51 Klein RS, 291
Engels EA, 371 Haumont P, 507 Kony S, 130
Eron JJ, 458 Hay P, 462 Kopicko J, 513
Etzel A, 185 Hecht FM, 435 Kost R, |
Eyre S, 63 Hejal R, 305 Kost RG, 332
Hemophilia Growth and Development Kostrikis LG, 298
Fang F, | Study, 466 Kpamegan E, 236
Fenaughty KE, 515 Hendel H, 507 Kreiss J, 170
Filho PB, 490 Heneine W, 93 Kreiss JK, 360
Fischer M, 397 Hertogs K, 145, 495, 501, 514 Kiicherer C, 266
Fisher DG, 515 Hilgartner MW, 466 Kumar PN, 320
Fisher M, 462 Hishikawa T, 512 Kumwenda N, 21
Folks TM, 93 Hittinger G, 44 Kunches LM, 263
Fong S, 56 Ho D, 332 Kwiatkowski CF, 483
Friedland GH, 118 Hofmann-Lehmann R, 8&
Frisch M, 371 Hollinger FB, 340 Lackritz E, 495
Fullem A, 21 Hong L, 298 Lafeuillade A, 44
Funk GA, 397 Hoots WK, 466 Lai S, 365
Furlan S, 332 Huang C, 246 Lambert M, 303
Fusco GP, 72 Huang K-L, 274 Lan Y-C, 274
Fusco JS, 72 Hugen PWH, 218 Landesman S, 236
Hughes MP, 360 Lang W, 458
Gadkari DA, 352 Hurley A, 1, 332 Lange J, S1
Galli L, 196 Lange JMA, 218
Galvao-Castro B, 490 Lanier R, 423
Gangakhedkar RR, 352 IIpgpboolkioto EGF,, 37226 Lantz O, 303
Gange SJ, 28 Larder B, 495, 501
Irwin CE, 208
Gazzard BG, 514 Laurent R, 137
Gebel HM, 103 Le Moing V, 151
George K, 176 Jacobson LP, 8>2 Lebigot S, 413
Gérard L, 182 Jen 1, 274 Ledergerber B, 397
Gilleece Y, 514 Jensen RH, 256 Lee F, 93
Gillini L, 326 John GC, 170 Leiser RJ, 443
Girardi E, 326 Johnson J, 1, 332 Lemiale F, 413
Goebel FD, 225 Johnson M, 159 Leport C, 480
Goedert JJ, 371 Jones L, 305 Leutenegger CM, 8
Goetz MB, 390 Joos B, 397 Levine AM, 28
Gold P, 8 Jorge MLSG, 185 Lewden C, 480
Gomes MS, 300 Joshi S, 21, 352 Lewis K, 381
Gomperts E, 466 Li R-J, 365
Gonzalez-Lahoz J, Li Y, 283
Gradstein S, 111 Kabugo M, 176 Li Z-J, 365
Graham NMH, 72 Kaldor JM, 283 Liang F-X, 365
Green MJ, 56 Kalish LA, 320 Liang S-L, 365
Green T, 93 Kalish M, 93 Liévre L, 130
Grosset J, 300 Kamya M, 176 Lin HJ, 340
Gubler B, 303 Kaneko H, 512 Lindsey JC, 449
Gueye NEN, 130 Kaneko Y, 512 Liu W, 365
Giinthard HF, 397 Kang S-Y, 164 Liu Y-C, 274
Gunzburg WH, 8 Kaplan EH, 118 Lo JC, 443
Gupta SM, 393 Kazatchkine MD, 193 Lounis N, 300
Kebba A, 495 Loveday C, S10
Haga T, 256 Kegeles S, 63 Lutz H, 8
Hahn T, 111 Kelly C, 21 Lynn H, 466
JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 26, No. 5, April 15, 2001
AUTHOR INDEX
MacQueen KM, 63 Ndoye J, 130 Read JS, 236
Madge S, 159 Nduati R, 170 Reboux G, 137
Mafigiri D, 176 Nelson G, 507 Reiner M, 170
Maillard A, 182 Nelson K, 21 Reisler RB, 93
Malach L, 111 Nelson PW, 405 Reiss G, 513
Mandaliya K, 360 Nesheim S, 93 Reiss P, 218
Margolis DM, 423 Newman M, 28 Respess R, 495, 501
Markowitz L, 345 Nicod P, 389 Revel M, 111
Markowitz M, 332 Nicoll A, 381 Reynes J, 36
Markowitz MH, | Nitayaphan S, 345 Rezza G, 377, 394, 473
Maron D, 170 Nkengasong JN, 501 Rich EA, 305
Masri-Lavine L, 28 Niiesch R, 191 Risbud AR, 3 5?
Mastro TD, 348 Nufiez M, 391 Rizzardini G, 25 99
Matheron S, 151 Robles R, 164
Matsumoto T, 512 O’Brien M, 513 Rodriguez C, 145
Mauger DT, 56 O’Brien S, 507 Rodriguez-Rosado R, 391
Maurice C, 501 Ogasawara H, 512 Roels TH, 501
Maynart M, 130 Okada M, 512 Roemer-Binns E, 507
Mazzolla R, 300 Oksenhendler E, 182 Rogers PA, 381
Mbori-Ngacha D, 170 Olinger GG, 103 Roongpisuthipong A, :
McDonald A, 283 Oller V, 391 Rousseau M-N, 36
McGarrigle C, 381 Opravil M, 397 Rozman M, 185
McGrath JW, 176 Overbaugh J, 360 Rugpao S, 2]
McGuire JF, 263
Padian N, 21
McKenna SM, 305
Pagano G, 458 Sabin CA, 462
McLellan E, 63 Palefsky JM, 256 Saha K, 199
Meehan TM, 263 Palmieri F, 326 Saifuddin M, 103
Meenhorst PL, 218
Pappagallo M, 473 Salmons B, 8
Mehendale S, 21 Para MF, 320 Sanchez ML, 28
Mehendale SM, 352 Sangtaweesin V, 348
Parada JP, 390
Meillet D, 137
Paranjape RS, 352 Santos M, 490
Melby T, 423
Parekh B, 348 Schambelan M, 443
Metro A, 130 Parry JV, 381 Schmidt B, 266
Metzger D, 63
Pauli G, 266 Schmitz M, 225
Michi GM, 225 Schulz TF, 182
Pedneault L, 458
Millard J, 458 Peeters M, 36, 501 Segondy M, 36
Miller V, S34 Peguillet I, 303 Segurado AAC, 185
Millon L, 137 Perelson AS, 405 Seidel D, 225
Mintz L, 320 Sekigawa I, 512
Pérez-Olmeda M, 145
Mittler JE, 405
Perinatal AIDS Collaborative Semba RD, 315, 352
Moat C, 193 Sengupta S, 63
Transmission Studies (PACTS)
Mock P, 348
members, 93 Senvewo R, 176
Mocroft A, 159 Perlis T, 164 Sepulveda C, 193
Monard S, | Peruzzi M, 196 Serraino D, 377
Monga B, 501
Petrosillo N, 326 Shaffer N, 348
Monod M, 137 Pezzotti P, 394, 473 Shah N, 315
Montes B, 36 Phair JP, 82 Sheldon J, 182
Moore AL, 159 Phillips AN, 159, 473 Shepherd ME, 352
Mooser V, 389 Sheppard H, 170
Piarroux R, 137
Moriondo M, 196 Pieniazek D, 495 Shibata GY, 185
Mortimer PP, 381 Pisapia M, 44 Shuter J, 291
Moss A, 435 SIDAK Study Group, 130
Pliner V, 93
Mostad SB, 360
Poggi C, 44 Simonds RJ, 348
Mugisha E, 176 Singhanati S, 348
Pollard RB, 320
Mugyenyi P, 495
Pozniak A, 462 Sinicco A, 473
Mulder JW, 218 Sipler AM, 390
Pozniak AL, 514
Mulligan K, 443
Prins JM, 218 Siriwasin W, 348
Murphy G, 381 Slatko GH, 72
Raffanti SR, 72 Smiley L, 1, 332
Naito T, 512 Raffi F, 480 Smith Rogers A, 449
Nasti G, 299 Rappaport J, 507 Snowden W, 458
Ndinya-Achola JO, 360 Ray K, 393 Sobel A, 480
JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 26, No. 5, April 15, 2001
520 AUTHOR INDEX
Soriano V, 145, 391 Tsai J-J, 274 Weinstein RA, 390
Soteriadou K, 300 Tuomala R, 236 Weiss L, 193
Sow PS, 130 Turner D, 423 Wietlisbach V, 389
Spear GT, 103 Wiktor SZ, 501
Strathdee SA, 82 Ubel PA, 56 Williams I, 462
Strauss RP, 63 Wilson D, 159
Sudre P, 389 Winkler C, 507
Vajaranant M, 236
Sukwit S, 345 Winkler CA, 466
Valadao E, 490
Suligoi B, 377 Wolfram J, 458
Svilar G, 176 Valdarchi C, 394, 473 Wong J-C, 274
van de Wijgert J, 21 Wong W-Y, 466
Taha T, 21 van der Meer JTM, 218 Wu M, 305
van der Poll T, 218
Tai VW, 443
Talal A, 332 Vanprapar N, 348 Yang J, 365
Verbiest W, 501
Talal AH, 1, 208 Yee H, 208
Vergne L, 36
Taoufik Y, 303 Young M, 28
Taramelli D, 300 Verrier B, 413 Young N, 348
Vesanen M, 1, 332
Tchetgen E, 118 Yu X-F, 365
Vierucci A, 196
Telenti A, 389
Vlahov D, 315
ten Veen JH, 218 Zaccarelli M, 473
Volberding P, S1
Thea DM, 93 Zagury D, 507
Thiakaki M, 300 Zagury J-F, 507
Thompson B, 236 Wagner TM, 394 Zazzi M, 196
Tirelli U, 299, 377 Wallach FR, 320 Zerhouni B, 199
Tisdale M, 458 Walli R, 225 Zhang J, 199
Tognazioli C, 300 Walter H, 266 Zhang L, 208, 332
Toossi Z, 305 Wang S, 246 Zheng Z, |
Torti C, 514 Wasi C, 348 Zhu Q-Y, 365
Trichavaroj R, 345 Watts H, 28 Zinzi D, 326
Trylesinski A, 303 Weidle PJ, 495 Zorrilla C, 236
JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 26, No. 5, April 15, 2001
JAIDS Journal of Acquired Immune Deficiency Syndromes
26:521-528 © 2001 Lippincott Williams & Wilkins, Inc., Philadelphia
Journal of Acquired Immune Deficiency Syndromes
Volume 26, 2001
Subject Index
Abacavir, open-label phase II trial of, 332 Antiretroviral-naive HIV-positive patients, nevirapine treat-
ABI Prism 7700 Sequence Detection System, multiplex RT- ment of, 462
PCR based on, 8 Antiretroviral resistance
Adherence, to HIV antiretroviral therapy, 435 analysis of in multidrug-resistant HIV-1 infection, 423
Adolescents, HIV-1 RNA levels and clinical disease develop- mycophenolate mofetil in therapy in, 423
ment in, 449 predictors of, S51
Adult T-cell leukemia/lymphoma, in AIDS patients, 371 Antiretroviral therapy
AF358746, HIV resistance to, 495 combination
AF358760, HIV resistance to, 495 apolipoprotein B metabolism and, 225
Africa determinants of heterogeneous adherence to, 82
antiretroviral resistance in, 495, 501] long-term failure of, S25
developing AIDS vaccine trials educational programs in, Pneumocystis carinii pneumonia recurrence and, 151
176 provider assessment of adherence to, 435
African-Americans, in HIV vaccine trials, 63 public health consequences of screening for adherence to,
AIDS 118
incidence of, adherence to HAART and, 118 reasons for failure of, S1
treatment, rationing of, 56 resistance to
vaccine trials educational programs for in Uganda, 176 among Ugandan patients, 495
validation of genetic case-control studies in, 507 in Céte d'Ivoire, 501
AIDS clinic, overweight in prognosis in, 291 response to by duration of HIV infection, 473
AIDS-defining diseases Apolipoprotein B metabolism, in HIV-infected patients with
in Australia, 283 antiretroviral combination therapy, 225
pattern of in HAART (letter), 394 Asia
AIDS-related opportunistic infections, chloroquine results in HIV-1 incidence among heroin users in, 365
(letter), 300 temporal trends and molecular epidemiology of HIV-|
Alloantibody, to major histocompatibility complex alloanti- subtypes in, 274
gens, 103 Aspartic proteinases, secreted, 137
Alloantigens, human antibodies to in HIV-1 lysis and neu- Australia, spectrum of AIDS-defining illnesses in, 283
tralization, 103
Alloimmunization, antibodies to major histocompatibility
complex alloantigens in, 103 BMS-232632, resistance to, $34
Amp-RT-reverse transcriptase, in HIV-1-infected neonate Body composition, with nucleoside analog reverse transcrip-
plasma, 93 tase inhibitors, 443
Amprenavir Body mass index, predictive value of in HIV care clinic, 291
open-label phase II trial of, 332 Brazil
in phase II trials cf dual protease inhbiitor therapy, 458 human T-cell lymphotropic virus type I infection among
Anal cancer, genetic changes with, 256 pregnant women in, 490
Anal intraepithelial neoplasia, detecting genetic changes in, seroprevalence and risk factors for HTLV-1/2 in HIV-
256 infected patients in, 185
Anemia BufferGel, phase I clinical trial of, 21
in HIV-infected injection drug users receiving HAART, Burst-forming unit, erythroid (BFU-E) colonies, in hemato-
315 poiesis, 111
in HIV-infected women, 28
Anti-infective agents, phase I clinical trial of, 21
Antibodies, to major histocompatibility complex alloantigens, Candidiasis
103 esophageal, in Australia, 283
Antiretroviral drugs oropharyngeal, in HIV-infected patients, 137
genotypic and phenotypic resistance assays for, S3 Carotenoids, low concentration of and HIV seroconversion in
resistance mutations to, 36 Pune, India, 352
522 SUBJECT INDEX
CCR5, HIV-1 replication through, 305 Cross-resistance
CCR2-64]/ alleles, in Tunisian population (letter), 298 to nonnucleoside reverse transcriptase inhibitors, S25
CCRS5A32 alleles, in Tunisian population (letter), 298 to protease inhibitors, $34
CD4 cell count Cryptococcosis, in Australia, 283
alternative methods for in developing countries (letter), Curdlan sulfate, inducing downmodulation of chemokine re-
193 ceptors (letter), 512
in antiretroviral-naive HIV-positive patients treated with CX3CRI polymorphism, genetic case-control studies and,
nevirapine, 462 507
Pneumocystis carinii pneumonia recurrence and, 151 Cytokines, with HAART, 44
with zidovudine and stavudine sequencing, 72 Cytomegalovirus
CD4* T cells PCR measures of, 320
alternative methods for enumerating in developing coun- related disease of in Australia, 283
tries (letter), 193
in HIV-1! perinatally infected children (letter), 196
proliferation of in GALT, 208 Delhi, HIV antibodies in replacement blood donors in (let-
CD8* T cells ter), 393
in HIV-1 perinatally infected children (letter), 196 Delivery mode, in postpartum morbidity among HIV-infected
productively infected in AIDS patients, 199 women, 236
Cell compartments, HIV-1 viral replicative capacity in, 397 Dementia, in nursing home residents with HIV, 246
Cellular resistance, to protease inhibitors, $34 Dermatitis, HTLV-1-associated infective, in pregnant women,
Cellular response, in multidrug-resistant HIV-1 infection, 423 490
Cervical cancer, incidence of in HIV-seropositive women Developing countries, alternative CD4 cell count methods in
before and after HAART, 377 (letter), 193
Cervicovaginal secretions, HIV-1 RNA quantitation in, 170 Diagnostic sensitivity, in HIV-1-infected neonates, 93
Chemokine receptors Disease duration, HAART response and, 473
curdlan sulfate inducing downmodulation of (letter), 512 Disease progression
genetic case-control studies of, 507 CX3CRI polymorphism and, 507
6-Chemokines, dysregulation of in lungs of HIV-1-infected HIV-1 RNA levels and, 449
patients, 305 DNA amplification, in drug resistance assay, $3
Children, CD4* and CD8* T lymphocyte recovery in (letter), Drug efficacy, in HIV viral dynamics, 405
196 Drug resistance
China, HIV-1 incidence among heroin users in, 365 adherence to HAART and, 118
Chloroquine, in AIDS-related opportunistic infections (letter), among Ugandan patients on antiretroviral therapy, 495
300 clinical utility of testing for, S51
Chronic disease, in HIV-infected injection drug users receiv- with dissociation of responses to HAART (letter), 196
ing HAART, 315 effects of, S1
Clinical presentation, in HIV-associated tuberculosis after genotypic and phenotypic, 266
HAART, 326 genotypic and phenotypic assays for, S3
Clinical procedures, for HIV-1 RNA detection and quantita- to nucleoside reverse transcriptase inhibitors, $10
tion in cervicovaginal secretions, 170 to protease inhibitors, S34
Clinical trials in recent seroconverters, 145
for cotrimoxazole in primary prevention for HIV-1-in- Drug treatment, in HIV risk reduction, 483
fected patients, 130 Drug users, provider assessment of adherence to HIV antiret-
education programs for in Uganda, 176 roviral therapy for, 435
Cohort studies, determinants of adherence to antiretroviral Dual-energy X-ray absorptiometry (DEXA), showing altered
therapy in, 82 fat distribution with nucleoside analog reverse tran-
Collaborations in HIV Outcomes Research (CHORUS) HIV scriptase inhibitors, 443
cohort study, zidovudine and stavudine sequencing in, Dual protease inhibitor therapy, phase II trial of, 458
72 Dyslipidemia, in HIV-infected individuals switched from
Combination therapy protease inhibitor-containing to efavirenz-containing
feasibility and efficacy of in chronic hepatitis C and HIV- regimens (letter), 389
coinfection (letter), 299
HIV-I viral replication and, 397
for multidrug-resistant HIV-1 infection, 423 Economics, of HIV medication rationing, 56
in patients failing protease inhibitor-containing regimens Educational programs, for AIDS vaccine, 176
(letter), 391] Efavirenz
Comparative genomic hybridization, in detecting genetic in combination therapy in patients failing protease inhibi-
changes with anal intraepithelial neoplasia, 256 tor-containing regimens (letter), 391
Complement, in HIV-1 primary isolate virions and, 103 persistent dyslipidemia in individual switched to regimens
Cote d'Ivoire, antiretroviral resistance in, 501 containing (letter), 389
Cotrimaxazole, in primary prevention for HIV-1-infected resistance to, $25
adults, 130 Efficacy, of twice-daily indinavir-ritnoavir combinations, 218
JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 26, No. 5, April 15, 2001
SUBJECT INDEX
Emergency departments, nonoccupational HIV postexposure Hemophilia Growth and Development Study, HIV-1 RNA
prophylaxis in, 263 levels and, 449
England, surveillance of HIV-1 subtypes in, 381 Hepatitis B virus, HIV-1 infection coexisting with, 340
Epidemiology Hepatitis C virus
of antiretroviral resistance in Africa, 501 chronic, in HIV-coinfected patients (letter), 299
of human T-cell lymphotropic virus type I infection in in hemophilia patients, 466
pregnant women in pregnant women in Brazil, 490 and HIV-1 incidence in China, 365
Erratum: “Patterns of Resistance Mutations to Antiretroviral HIV-1 infection coexistence with, 340
Drugs in Extensively Treated HIV-1-Infected Patients Heroin users, HIV-1 incidence among in China, 365
with Failure of Highly Active Antiretroviral Therapy” Heterosexual transmission
(26:36-43), 395 of HIV-1 subtypes in England and Wales, 381
Ethics, of HIV medication rationing, 56
of HIV-1 subtypes in Taiwan, 274
Highly active antiretroviral therapy (HAART)
AIDS-defining diseases in persons responding to (letter),
Fat distribution, altered in HIV-positive men on nucleoside
394
analog reverse transcriptase inhibitor therapy, 443
Feline immunodeficiency virus, multiplex RT-PCR for, 8 changing clinical presentation and survival in HIV-associ-
Female genital tract, HIV-1 cell shedding in with selenium ated tuberculosis after, 326
deficiency, 360 with cytokines to induce HIV-1 remission, 44
Female sex workers, temporal trends and molecular epidemi- dissociation of responses to (letter), 196
ology of HIV-1 subtypes in, 274 effects on HIV-1 in GALT, |
Fitness, in nonnucleoside reverse transcriptase inhibitor resis- gender differences in virologic response to, 159
tance, $25 improvement of anemia among HIV-infected injection
Fluorogenic probes, in multiplex RT-PCR, 8 drug users receiving, 315
in interleukin-10 and interleukin-12 expression, 303
invasive cervical cancer and, 377
Gastrointestinal adverse events, during pregnancy in women mortality in HIV-infected cohort started on, 480
prescribed nelfinavir (letter), 513 Pneumocystis carinii pneumonia recurrence in, | 51
Gastrointestinal system, lymphocyte proliferation in, 208 provider assessment of adherence to, 435
Gay men, in HIV vaccine trials, 63 public health consequences of screening for adherence to,
Gender, in virologic response to HIV treatment, 159 118
Genetic case-control studies, validation of, 507 reasons for discontinuing in proteinase inhibitor-naive
Genetic changes, in anal intraepithelial neoplasia, 256 HIV-infected patients (letter), 191
Genetics of the Resistance to Infection by the Immunodefi- resistance mutations in failure of, 36
ciency Virus (GRIV) study, validation of, 507 response to by duration of HIV infection, 473
Genital secretions, HIV-1] RNA quantitation in, 170 HIV-1 DNA
Genotype assays, for drug resistance, $1, S3
with HAART and cytokines, 44
Genotypic HIV-1 drug resistance
reverse transcriptase activity and in neonate plasma, 93
frequency of in therapy-naive patients, 266
HIV-1 genotypic resistance, with HAART failure, 36
in seroconverters, 145
HIV-1-infected cell shedding, selenium deficiency and, 360
Genotypic resistance
HIV-1 infection
in HAART failure, 36
-chemokine dysregulation in lungs in, 305
prevalence of in Céte d’Ivoire, 501
in diagnosis and evaluation of hepatitis C virus, 340
Genotypic resistance assays
HAART and cytokines to induce remission of, 44
clinical utility of, S51
hepatitis C viral luad and in hemophilia patients, 466
interpretation of, S10
incidence of in heroin users in China, 365
Geographic variation, in AIDS-defining illnesses in Australia,
lymphocyte proliferation in GALT and, 208
283
multidrug-resistant, mycophenolate mofetil in therapy for,
Granulomonocytic colony-forming cells (GM-CFC), in hema-
topoiesis, 111 423
Gut-associated lymphoid tissue in neonates, reverse transcriptase activity in plasma of, 93
antiretroviral therapy effects on HIV-1 in, | open-label phase II trial of amprenavir, abacavir, and
HIV-! infection effect on lymphocyte proliferation in, 208 fixed-dose zidovudine/lamivudine in, 332
pathogenesis of
hepatitis C viral load and in hemophilia patients, 466
Health care provider, assessment of adherence to HIV anti- productively infected CD8* T cells in AIDS patients
retroviral therapy, 435 and, 199
Health care rationing, for HIV, 56 primary prevention with cotrimaxazole in, 130
Health policy, on HIV medication rationing, 56 seroprevalence and risk factors for HTLV-1/2 in, 185
Hematopoiesis, recombinant TNF-alpha binding protein in, HIV-1 isolate virions, MHC alloantibodies in lysis and neu-
111 tralization of, 103
Hemoglobin, in HIV-infected injection drug users receiving HIV-1 replication, quantification of in different cell compart-
HAART, 315 ments, 397
JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 26, No. 5, April 15, 2001
524 SUBJECT INDEX
HIV-1 RNA Human herpesvirus 8, seroprevalence for in HIV-associated
in clinical disease in adolescent populations, 449 non-Hodgkin’s lymphoma patients, 182
with HAART and cytokines, 44 Human papillomavirus, genetic changes with, 256
techniques for detection and quantitation of in cervicovagi- Human T-cell lymphotropic virus type | (HTLV-1) infection
nal secretions, 170 in pregnant women in Brazil, 490
in Thai men and women with subtype E infections, 345 seroprevalence and risk factors for, 185
with zidovudine and stavudine sequencing, 72 Human T-cell lymphotropic virus type 2 (HTLV-2) infection,
HIV-1 subtypes seroprevalence and risk factors for, 185
national surveillance of, 381 Hypertriglyceridemia, apolipoprotein B metabolistn and, 225
temporal trends and molecular epidemiology of in Taiwan,
274
IC;,, in drug resistance assay, $3
HIV-1 tropism, pathogenesis and, 199
Immune intervention, with HAART and cytokines, 44
HIV antibodies, in replacement blood donors (letter), 393
Immunogenicity, of recombinant envelope glycoproteins de-
HIV antiretroviral therapy
rived from T-cell line-adapted isolates or primary
determinants of heterogeneous adherence to, 82
HIV isolates, 413
provider assessment of adherence to, 435
Immunology, of HAART on HIV-1! in GALT, |
HIV-associated lymphoma, human herpesvirus 8 seropreva-
India
lence in, 182
HIV antibodies in replacement blood donors in (letter),
HIV care clinic, overweight and prognosis in, 29]
393
HIV-chronic hepatitis C coinfection (letter), 299 low carotenoid concentration and risk of HIV seroconver-
HIV drug resistance sion in, 352
among Ugandan patients on antiretroviral therapy, 495 Indinavir
in Cote dIvoire, 501 in phase II trials of dual protease inhibitor therapy, 458
HIV infection twice-daily regimen of, 218
anemia prevalence in women with, 28 Informed consent, for AIDS vaccine trials, 176
curdlan sulfate inducing downmodulation of chemokine Injection drug users
receptors in suppression of (letter), 512 HIV-1 subtypes in, 274
dementia and in nursing home residents, 246 HIV seroprevalence and needle sharing among, 164
pathogenesis of, drug efficacy and eclipse phase of viral in HIV vaccine trials, 63
life cycle in, 405 improvement of anemia with HAART among, 315
HIV postexposure prophylaxis, nonoccupational, 263 methadone maintenance as HIV risk reduction in, 483
HIV prevention, phase I clinical trial of BufferGel in, 21 provider assessment of adherence to HIV antiretroviral
HIV Prevention Trials Network (NIVNET), 63 therapy for, 435
HIV risk reduction, methadone maintenance as, 483 syringe type preference among (letter), 515
HIV RNA, in antiretroviral-naive HIV-positive patients Insulin resistance, apolipoprotein B metabolism and, 225
treated with nevirapine, 462 Interferon-a2b, feasibility and efficacy of in chronic hepatitis
HIV seroconversion C and HIV-coinfection (letter), 299
invasive cervical cancer and, 377 Interleukin-2, with HAART to induce HIV-1I remission, 44
low carotenoid concentration and risk of, 352 Interleukin-10, HAART effect on expression of, 303
HIV seroconverters, response to HAART in, 473 Interleukin-12, HAART effect on expression of, 303
HIV seroprevalence, needle sharing and, 164 Intestinal mucosa
HIV subtypes antiretroviral therapy effects on HIV-1! in, |
drug resistance of, 495 HIV-1 infection effect on lymphocyte proliferation in, 208
resistance to antiretroviral therapy in Cote dIvoire, 501 Invasive cervical cancer, incidence of in HIV-seropositive
HIV transmission, primary genotypic and phenotypic HIV-| women before and after HAART, 377
drug resistance and, 145
HIV treatment
Ki-67 antigen, in lymphocyte proliferation in GALT, 208
gender differences in virologic response to, 159
Kinetic modeling, of apolipoprotein B metabolism in HIV-
zidovudine and stavudine sequencing in, 72
infected patients with antiretroviral combination
HIV vaccine therapy, 225
educational programs for, 176
willingness to volunteer in trials for, 63
HIV viral dynamics, drug efficacy and eclipse phase of viral Lamivudine
life cycle in, 405 HIV resistance to in Uganda, 495
HIV viral load, in Thai men and women with subtype E in- open-label phase II trial of, 332
fections, 345 resistance to, S10
HLA, in HIV-1! immunization, 103 Latin America
Homeless, provider assessment of adherence to HIV antiret- human T-cell lymphotropic virus type I infection in preg-
roviral therapy for, 435 nant women in, 490
Hospital emergency departments, nonoccupational HIV post- seroprevalence and risk factors for HTLV-1/2 in HIV-in-
exposure prophylaxis in, 263 fected patients in, 185
JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 26, No. 5, April 15, 2001
SUBJECT INDEX
Letters to editor Maintenance prophylaxis, Pneumocystis carinii pneumonia
chronic hepatitis C in HIV-coinfected patients: feasibility recurrence and, 151
and efficacy of interferon-a2b and ribavirin combina- Major histocompatibility complex alloantigens, human anti-
tion therapy, 299 bodies to in HIV-1 lysis and neutralization, 103
comparative assessment of five alternative methods for Mathematical models
CD4* T-lymphocyte enumeration for implementation for adherence to HAART, 118
in developing countries, 193 for drug efficacy and eclipse phase of viral life cycle, 405
contrasting frequencies of CCR5A32 and CCR2-64/ alleles for HIV-1 viral replicative capacity in different cell com-
in the Tunisian population, 298 partments, 397
curdlan sulfate induces the downmodulation of chemokine Medication adherence
receptors leading to suppression of HIV infection, determinants of, 82
S12 public health consequences of screening for, 118
different pattern of AIDS-defining diseases in persons re- Methadone maintenance, as HIV risk reduction with injecting
sponding to highly active antiretroviral therapy, 394 drug users, 483
dissociation of responses to HAART: notwithstanding vi- Microbicides, phase | clinical trial of, 21
rologic failure and virus drug resistance, 196 Minimum data set, in analysis of dementia in nursing home
experimental results on chloroquine and AIDS-related op- residents with HIV, 246
portunistic infections, 300 Molecular epidemiology
lack of association between pregnancy and selected gastro- of HIV-1 infection in Taiwan, 274
intestinal adverse events among women prescribed of HIV-1 subtypes in England and Wales, 381
nelfinavir, 513 Monocyte chemotactic protein (MCP)-1, dysregulation of in
performance of a quadruple combination including nelfina- lungs of HIV-1-infected patients, 305
vir plus efavirenz in naive subjects with high baseiine Mortality, in HIV-infected cohort started on a protease
viral load and in patients failing protease inhibitor- inhibitor-containing therapy, 480
containing regimens, 390 Mother-to-infant transmission
persistent dyslipidemia in HIV-infected individuals delivery mode and, 236
switched from a protease inhibitor-containing to an HIV seroconversion during pregnancy and, 348
efavirenz-containing regimen, 389 Mucosal immunity, anti-Candida albicans, 137
prevalence of HIV antibodies in replacement blood donors Multicenter AIDS cohort studies, determinants of adherence
in Delhi, India, 393 to antiretroviral therapy in, 82
reasons for discontinuation of first highly active antiretro- Multidrug-resistant HIV-1 infection, mycophenolate mofetil
viral therapy in a cohort of proteinase inhibitor-naive in therapy for, 423
HIV-infected patients, 191 Multiple-drug resistance, international perspective on, S10
R211K and L214F do not invariably confer high level Mutations
phenotypic resistance to thymidine analogs in zidovu- in antiretroviral drug resistance with HAART failure, 36
dine-naive patients with MI84V, 514 interactions between, S34
syringe type preference among injection drug users, 515 in resistance to nonnucleoside reverse transcriptase inhibi-
variations in institutional review board decisions for HIV tors, S25
quality of care studies: a potential source of study in reverse transcriptase inhibitor resistance, S10
bias, 390 M184V mutation
L214F, phenotypic resistance to thymidine analogs with (let- in antiretroviral resistance, S10
ter), 514 R211K and L214F in phenotypic resistance to thymidine
Lipodystrophy, with nucleoside analog reverse transcriptase analogs with (letter), 514
inhibitors, 443 Mycobacterium avium complex infection, in Australia, 283
Long-term follow-up, of antiretroviral-naive HIV-positive Mycophenolate mofetil, in multidrug-resistant HIV-1 infec-
patients treated with nevirapine, 462 tion therapy, 423
Longitudinal study, of anti-Candida albicans mucosal immu- Mycophenolic acid, in multidrug-resistant HIV-1 infection
nity against aspartic proteinases in HIV-infected pa- therapy, 423
tients, 137 Mycosis fungoides, in AIDS patients, 371
Lopinavir, resistance to, S34
Lungs, B-chemokine dysregulation in, 305
Lyinphocytes Needle sharing, HIV seroprevalence and, 164
HIV-1! infection effect on proliferation of, 208 Nelfinavir
productively infected in HIV-1 patients, 199 in combination therapy in patients failing protease inhibi-
Lymphomas, risk of in AIDS patients, 371 tor-containing regimens (letter), 391
in gastrointestinal adverse events during pregnancy (letter),
Macrophage inflammatory protein (MIP-1a), dysregulation ais
of in lungs of HIV-1-infected patients, 305 in phase I trials of dual protease inhbiitor therapy, 458
Macrophage inflammatory protein (MIP-18), dysregulation Neonates, reverse transcriptase activity in plasma of, 93
of in lungs of HIV-1-infected patients, 305 Nevirapine
Madrid, primary genotypic and phenotypic HIV-1 drug resis- antiretroviral-naive HIV-positive patients treated with, 462
tance in recent seroconverters in, 145 resistance to, S25
JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 26, No. 5, April 15, 2001
526 SUBJECT INDEX
New York, needle sharing and HIV seroprevalence among HIV seroconversion during, 348
injection drug users in, 164 human T-cell lymphotropic virus type I infection during,
Non-Hodgkin’s lymphoma 490,
in AIDS patients, 371 Prevention
HIV-associated, human herpesvirus 8 seroprevalence in, with cotrimaxazole, 130
182 willingness to volunteer in HIV vaccine trials for, 63
Nonnucleoside reverse transcriptase inhibitors, resistance to, Primary HIV isolates, recombinant envelope glycoproteins
S25 derived from, 413
Nucleic acid sequence-based amplification, in HIV-1-infected Prognosis
neonates, 93 in HIV-1-infected neonates, 93
Nucleoside reverse transcriptase inhibitors overweight in urban HIV care clinic, 291
altered fat distribution with, 443 Prophylaxis, HIV postexposure, in hospital emergency de-
resistance to, S10 partments, 263
sequencing of in HIV treatment plans, 72 Protease inhibitors
Nursing home residents, with HIV and dementia using mini- altered fat distribution with, 443
mum data set, 246 apolipoprotein B metabolism and, 225
Nutritional deficiency, HIV-1 cell shedding and, 360 dual therapy of, phase II trials of, 458
improved anemia with, 315
mortality in HIV-infected cohort started on, 480
Obstetrics, HTLV-1 infection in, 490 in multidrug-resistant HIV-1 infection therapy, 423
Opportunistic infections, chloroquine results in (letter), 300 persistent dyslipidemia in individual switched from (letter),
Oropharyngeal candidiasis, in HIV-infected patients, 137 389
Overweight, in prognosis in urban HIV care clinic, 291 quadruple combination performance in patients failing
regimens containing (letter), 391
resistance to, S34
Pathogenesis, T cell infection and, 199 Public health, screening patients for HAART adherence and,
Perinatal transmission 118
HIV seroconversion during pregnancy and, 348 Public policy, on HIV medication rationing, 56
virologic failure and HAART resistance with (letter), 196 Puerto Rico, needle sharing and HIV seroprevalence among
Pharmacokinetics, of twice-daily indinavir-ritnoavir combina- injection drug users in, 164
tions, 218
Phase [ trial
of topical microbicide BufferGel, 21 Quadruple combination therapy, in patients failing protease
Phase I] trial inhibitor-containing regimens (letter), 391
of amprenavir, abacavir, and fixed-dose Quality of care, institutional review board decisions in (let-
zidovudine/lamivudine, 332 ter), 390
of dual protease inhibitor therapy, 458 Quality of life, in advanced HIV patients requiring transfu-
Phenotype resistance assays, S1, S3 sions, 320
Phenotypic resistance
HIV-1 drug
frequency of in therapy-naive patients, 266 RANTES, dysregulation of in lungs of HIV-1-infected pa-
in seroconverters, 145 tients, 305
prevalence of in Céte d'Ivoire, 501 Rash, nevirapine-associated, 462
R211K and L214F in (letter), 514 Rationing, of HIV medications, 56
Phenotypic resistance assays Recombinant envelope glycoproteins, immunogenicity of,
clinical utility of, S51 413
Pneumocystis carinii pneumonia, recurrence of in HIV pa- Recombinant tumor necrosis factor-alpha binding protein, in
tients on HAART, 151 hematopoiesis of HIV-infected patients, 111
Point mutations, in resistance to nonnucleoside reverse tran- Replacement blood donors, HIV antibodies in (letter), 393
scriptase inhibitors, S25 Reproductive rate, of HIV-1 virus, 397
Polymerase chain reaction Research participation, in HIV vaccine trials, 63
for cytomegalovirus in HIV-infected patients requiring Residual viral pool, with HAART and cytokines, 44
transfusions, 320 Resistance assays
real-time, multiplex, for FIV, 8 clinical utility of, S51
reverse transcriptase activity for in HIV-1-infected neo- interpretation of, S1
nates, 93 phenotypic and genotypic, S3
Polymorphism, genetic case-control studies and, 507 Resistance mutations
Postpartum morbidity, delivery mode and among HIV-in- among Ugandan patients on antiretroviral therapy, 495
fected women, 236 to antiretroviral therapy in Cote d'Ivoire, 501
Pregnancy Reverse transcriptase activity, early detection of in HIV-1-
gastrointestinal adverse events and in women prescribed infected neonate plasma, 93
nelfinavir (letter), 513 Reverse transcriptase enzyme, resistance to, S10
JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 26, No. 5, April 15, 2001